In an Op-ed for Psilocybin Alpha, British MP Crispin Blunt, who launched the Conservative Drug Policy Reform Group, discusses this apparent mismatch between the public’s perception of psilocybin-assisted psychotherapy and the Home Office’s policies.
Nevertheless, 58% support law changes to permit terminally ill patients to access it with therapy—a demographic for which it is already clinically evidenced to offer otherwise-unattainable solace and peace-of-mind. Tellingly, this rose to 68% with education on clinical research and similar policy advances elsewhere in the world, and opposition shrank to just 9% – the remaining proportion just not having enough information to make a decision.
The results of Psilonautica’s population sampling with DrugScience say more about the compassion and discernment of the British public than they do about psilocybin.
Read the full piece here.
VICE: Psychedelics Patent Claim Raises Questions From Researchers Who Say They Did It First
In her latest piece covering the emergent psychedelics sector, Shayla Love discusses a recent patent application by CB Therapeutics covered in our Bulletin on May 22nd.
The application, published on May 20, was originally filed on November 15, 2019. (Patent applications are kept secret for 18 months.) First reported by Psilocybin Alpha, the application has claims on organisms genetically modified to produce psilocybin by giving them the genes for enzymes that make the compound naturally in mushrooms.
It’s a promising approach to make psilocybin in the large quantities needed to do research, or, one day, treat various mental health conditions. In a press release, CB Therapeutics wrote that its application represented a “major breakthrough in the biosynthesis of psilocybin.”
But the four enzymes in the patent application were discovered in 2017 when Blei was getting his PhD at the Leibniz Institute for Natural Product Research and Infection Biology. He published a scientific paper on those enzymes with his colleagues Janis Fricke and Dirk Hoffmeister in the German journal Angewandte Chemie International Edition; they wrote in the paper how their findings could be used to produce psilocybin by “using engineered microbial hosts.”
Their research was not cited in the patent application. Yet, if this patent application was granted as is, it could block others—including Blei, who is now the co-founder of Mimosa Therapeutics—from producing psilocybin using host organisms with these enzymes.
Beyond this specific application, Love’s article covers a number of patent-related conventions that are relevant to the broader psychedelics space. Read the full piece here.
Business Insider: Experts share how a brewing fight could shape the future of the $100 billion psychedelics industry
Patents were also the focus of a Business Insider article this week, noting that “the conflict over patents has the potential to shape the future of the psychedelics lanscape.”
The story focuses on COMPASS Pathways’ patents (and applications), and Carey Turnbull’s opposition.
A decade ago, Carey Turnbull was at the forefront of a movement to fund research into the medical potential of psychedelics.
Now, the businessman turned psychedelics philanthropist has found a new cause: fighting to keep the knowledge and discoveries that undergird the psychedelics industry in the public domain.
He recently estimated that he’s spent about $400,000 of his own money on a fight against what he and others in the psychedelics community say are overreaching patents. For now, they’re taking aim at patents filed by the psychedelics-industry giant Compass Pathways, a $1.4 billion firm focused on medical uses of psilocybin, the active ingredient in magic mushrooms.
Read the full story here.